AbbVie Korea will conduct a clinical trial in Korea to expand the indication of its atopic dermatitis drug Rinvoq (upadacitinib) to children aged 2 to 12 years old.

On the 24th, the Ministry of Food and Drug Safety (MFDS) approved AbbVie’s application to initiate a Phase III, open-label, blinded trial (START UP) to compare the safety and efficacy of Dupixent (dupilumab) vs RInvoq in children aged 2 to 12 years with moderate-to-severe atopic dermatitis.

The trial will be conducted at Gangnam Sacred Heart Hospital, Chung-Ang University Hospital, Konkuk University Medical Center, Korea University Ansan Hospital, Soonchunhyang University Hospital Bucheon, and Seoul National University Hospi